Press Releases

Grifols reaches strategic alliance with Haier Group and raises approximately USD 1.8 billion December 29 2023

Victor Grifols Roura announces retirement from the Board of Directors; Albert Grifols Coma-Cros appointed as new Board Member December 19 2023

Grifols renews its inclusion in the Dow Jones Sustainability Indices as one of the world s most sustainable companies December 11 2023

Grifols accelerates EBITDA margin expansion to 25.1% and further improves its operating performance November 2 2023

Grifols delivers 15% revenue growth, accelerates margin expansion in Q2 and raises guidance for FY23 July 27 2023

Grifols delivers strong first quarter financials with 23% revenue growth and an Adjusted EBITDA margin above guidance of 21% May 9 2023

Grifols realigns management structure to accelerate company performance and simplify its corporate governance May 8 2023

Grifols delivers strong 2022 performance and is positioned for sustainable future growth February 28 2023

Thomas Glanzmann new Grifols Executive Chairman, after Steven F. Mayer resignation February 21 2023

Grifols announces comprehensive operational improvement plan including EUR 400 million annualized cost savings initiative February 15 2023

Grifols included in Bloomberg Gender-Equality Index for the third consecutive year for its leadership in equality, diversity and inclusion January 31 2023

Grifols recognized as one of the world’s most sustainable companies by Dow Jones Sustainability Index for third consecutive year December 12 2022

Grifols’ Biopharma delivers robust 34% operational growth in Q3, driving revenues to EUR 4,351m in the first nine months of 2022 November 8 2022

Grifols invites to listen to webcast of November 8 Conference Call with Analysts November 4 2022

Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson October 3 2022

Board of Directors communication in the context of considerable geopolitical uncertainty and market volatility September 26 2022

Grifols’ credit rating reaffirmed by Moody’s and Fitch based on strong fundamentals and improving performance September 23 2022

Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada September 7 2022

Grifols’ business momentum delivers EUR 2,810 million in revenues and EUR 618 million in EBITDA as plasma collections accelerate July 28 2022

Grifols highlights the acceleration of its operating performance and reiterates its strong commitment to debt reduction June 16 2022

Grifols highlights an increase in plasma and underscores innovation and sustainability as key growth pillars in its AGM June 10 2022

Business Update 1Q 2022: Grifols accelerating plasma recovery while enhancing performance May 6 2022

Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation April 25 2022

Grifols demonstrates resilient performance despite a challenging backdrop while recovery in plasma collection gains momentum February 28 2022

Grifols signs global collaboration agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis February 24 2022

Grifols maintains its standing in the Bloomberg Gender-Equality Index for its commitment to equality January 26 2022

Grifols achieves a high level of acceptance of its PTO to Biotest and advances on its strategic transaction January 26 2022

Grifols announces the expiration of the Asset sale Offer January 11 2022

Grifols moves forward with its divestment plan by agreeing to sell VCN Biosciences December 14 2021

Grifols announces the commencement of an Asset sale Offer December 13 2021

Grifols and GIC obtain authorization for their strategic agreement for USD 1 billion November 17 2021

Grifols is included on the Dow Jones Sustainability World Index November 15 2021

Grifols advances on the execution of its strategic plan November 11 2021

Grifols earns approval for the voluntary public tender offer of Biotest and advances its strategy to increase the availability of plasma-derived medicines October 26 2021

Grifols increases access to plasma-derived therapies as part of its commitment to donors and patients October 13 2021

Grifols divests its hemostasis technology business for USD 25 million October 6 2021

Grifols closes its EUR 2 billion bond issuance to finance its investment in Biotest October 5 2021

Grifols earns its first Fitch corporate rating with a BB- and stable outlook September 27 2021

Grifols announces its investment in Biotest September 17 2021

Grifols advances on its strategic investment from GIC with 90% of consents from its notes holders and lenders August 16 2021

Grifols signs an agreement with ImmunoTek to open 21 plasma centers and further advances on its expansion plan July 30 2021

The Bioscience Division grows 5.1% in the second quarter and raises first-half revenues to EUR 2,537 million July 29 2021

Grifols endorses its commitment to a responsible business model and support of the 2030 Agenda for Sustainable Development by formally joining the United Nations Global Compact July 20 2021

Grifols announces a strategic investment from GIC of USD 1 billion June 30 2021

Grifols reaffirms its commitment to sustainability and innovation in its AGM and celebrates its 15th anniversary of being listed May 21 2021

Grifols maintains its revenues and operational levels while enhancing its innovation strategy and securing its plasma supply May 4 2021

Grifols advances in the execution of its expansion plan with the acquisition of 7 plasma centers in the U.S. April 7 2021

Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19 April 2 2021

Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins March 9 2021

Grifols publishes its 2020 Integrated Annual Report as part of its commitment to sustainability March 4 2021

Grifols acquires 25 U.S.-based plasma centers from BPL ensuring one million additional liters for fractionation March 1 2021

Grifols increases its revenues to 5,340 M€ and continues to demonstrate its resilience and commitment to sustainable growth February 26 2021

Grifols is included in the Bloomberg Gender-Equality Index for its commitment to gender equality January 27 2021

Grifols creates a Sustainability Committee to strengthen its long-term sustainable growth model December 16 2020

Grifols is included on Euronext Vigeo indices and recognized once again as one of the world's most sustainable companies December 9 2020

Strategic alliance between Grifols and the Egyptian government to boost plasma-derived medicines self-sufficiency in the Middle East and Africa November 24 2020

The Dow Jones Sustainability Index recognizes Grifols as one of the world’s most sustainable companies November 16 2020

Grifols consolidates its Hospital Division as a reference in innovative solutions with the acquisition of the 49% stake in MedKeeper November 9 2020

Grifols continues delivering solid revenue and earnings growth driven by the Bioscience and Diagnostic Divisions November 5 2020

Grifols underlines the importance of plasma in its Annual General Shareholders’ Meeting October 9 2020

Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S. October 1 2020

Grifols more committed than ever to its values and long-term vision six months into the pandemic September 14 2020

Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome September 7 2020

Grifols revenues grow 10.5% to EUR 2,677 million driven by the Bioscience Division July 30 2020

Grifols delivers first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials July 28 2020

Results of Grifols’ AMBAR clinical trial published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association July 27 2020

Grifols acquires 10% stake in Bloodbuy, cloud-based marketplace for blood products July 23 2020

Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million July 20 2020

Grifols starts commercializing TAVLESSE^® in Europe, diversifying its medicines portfolio July 9 2020

Grifols starts production of its hyperimmune immunoglobulin as a potential passive immune therapy against COVID-19 June 11 2020

Grifols reinforces its liquidity position to EUR 1,700 million May 7 2020

Grifols maintains its operational levels and continues to reinforce its commitment to society April 21 2020

Grifols continues to reinforce its commitment to all stakeholders as a response to COVID-19 April 21 2020

Grifols and Shanghai RAAS close their strategic alliance in China March 27 2020

Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19 March 25 2020

Grifols reinforces its commitment to all stakeholders as a response to the COVID-19 outbreak March 18 2020

Grifols reaches revenue of EUR 5,100 million, a 13.6% increase, and raises its profits to EUR 625 million February 27 2020

Grifols and the Public Investment Fund of Saudi Arabia to boost plasma medicines self-supply in the region February 18 2020

Grifols to launch TAVLESSE^® in Europe and Turkey to continue reinforcing its commercial strategy and commitment to patients January 16 2020

Grifols launches XEMBIFY^® 20% subcutaneous immunoglobulin, a new Primary Immunodeficiency treatment December 12 2019

Grifols presents its latest Alzheimer’s clinical trial data December 6 2019

Grifols introduces its first plasma protein-based biosurgery product December 4 2019

Grifols completes its debt-refinancing in record time and with strong acceptance for EUR 5,800 million November 15 2019

Grifols and Shanghai RAAS obtain authorization for their strategic alliance in China November 13 2019

Grifols increases its revenues by 14.5% to EUR 3,738 million October 29 2019

Grifols increases its revenues by 14.3% to EUR 2,423 million, driven by its strategic growth plan July 31 2019

Grifols presents additional encouraging Alzheimer’s trial results at AAIC July 16 2019

Grifols announces FDA approval of Xembify^®, 20% subcutaneous immunoglobulin for primary immunodeficiencies July 4 2019

Grifols reinforces its long-term and sustainable growth strategy with EUR 1,400 million in capital investments in 2018-2022 May 24 2019

Grifols publishes its 2018 Corporate Responsibility Report as part of its commitment to transparency May 23 2019

Grifols reports 13% revenue growth to EUR 1,157 million and confirms its solid operational performance May 7 2019

Grifols presents new data to support the effectiveness of its clinical trial to treat Alzheimer's March 29 2019

Grifols enters a strategic alliance with Shanghai RAAS to boost growth of its plasma-derived products and diagnostic solutions in China March 7 2019

Grifols reports EUR 4,487 million in revenues, with 9.2% operating growth and EUR 597 million in net profit February 28 2019

Grifols Announces Collaboration and License Agreement with Rigel Pharmaceuticals January 23 2019